These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 33739964)

  • 21. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
    Fiala C; Diamandis EP
    Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy.
    Wang R; Wang B; Zhang H; Liao X; Shi B; Zhou Y; Zhou C; Yan Y; Zhang W; Wang K; Ge G; Ren Y; Tang X; Gan B; He J; Niu L
    Breast; 2024 Aug; 76():103738. PubMed ID: 38685149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review ctDNA and Breast Cancer.
    Clatot F
    Recent Results Cancer Res; 2020; 215():231-252. PubMed ID: 31605232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
    Abbosh C; Birkbak NJ; Swanton C
    Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
    Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
    Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.
    Zavarykina TM; Lomskova PK; Pronina IV; Khokhlova SV; Stenina MB; Sukhikh GT
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.
    McDonald BR; Contente-Cuomo T; Sammut SJ; Odenheimer-Bergman A; Ernst B; Perdigones N; Chin SF; Farooq M; Mejia R; Cronin PA; Anderson KS; Kosiorek HE; Northfelt DW; McCullough AE; Patel BK; Weitzel JN; Slavin TP; Caldas C; Pockaj BA; Murtaza M
    Sci Transl Med; 2019 Aug; 11(504):. PubMed ID: 31391323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
    Chen M; Zhao H
    Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
    Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
    Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes.
    Paramathas S; Guha T; Pugh TJ; Malkin D; Villani A
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28758. PubMed ID: 33047872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges.
    Matsutani A; Udagawa C; Matsunaga Y; Nakamura S; Zembutsu H
    Pharmacogenomics; 2020 Apr; 21(5):359-367. PubMed ID: 32284011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liquid biopsy: unlocking the potentials of cell-free DNA.
    Chu D; Park BH
    Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer.
    Chen K; Kang G; Zhao H; Zhang K; Zhang J; Yang F; Wang J
    Expert Rev Mol Diagn; 2019 May; 19(5):419-427. PubMed ID: 30905203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumor DNA: current challenges for clinical utility.
    Dang DK; Park BH
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma.
    De Simoni E; Spagnolo F; Gandini S; Gaeta A; Rizzetto G; Molinelli E; Simonetti O; Offidani A; Queirolo P
    Cancer Treat Rev; 2024 Sep; 129():102788. PubMed ID: 38908229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
    Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
    Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.